###begin article-title 0
Alterations of E-cadherin and beta-catenin in gastric cancer
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
The E-cadherin-catenin complex plays a crucial role in epithelial cell-cell adhesion and in the maintenance of tissue architecture. Perturbation in the expression or function of this complex results in loss of intercellular adhesion, with possible consequent cell transformation and tumour progression.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
We studied the alterations of E-cadherin and beta-catenin in a set of 50 primary gastric tumours by using loss of heterozygosity (LOH) analysis, gene mutation screening, detection of aberrant transcripts and immunohistochemistry (IHC).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
A high frequency (75%) of LOH was detected at 16q22.1 containing E-cadherin locus. Three cases (6%) showed the identical missense mutation, A592T. This mutation is not likely to contribute strongly to the carcinogenesis of gastric cancer, because a low frequency (1.6%) of this mutation was also found in 187 normal individuals. We also detected a low frequency (0.36%, 0%) of this mutation in 280 breast tumours and 444 other tumours, including colon and rectum, lung, endometrium, ovary, testis, kidney, thyroid carcinomas and sarcomas, respectively. We also analyzed the aberrant E-cadherin mRNAs in the gastric tumours and found that 7 tumours (18%) had aberrant mRNAs in addition to the normal mRNA. These aberrant mRNAs may produce abnormal E-cadherin molecules, resulting in weak cell-cell adhesion and invasive behaviour of carcinoma cells. Reduced expression of E-cadherin and beta-catenin was identified at the frequency of 42% and 28%, respectively. Specially, 11 tumours (22%) exhibited positive cytoplasmic staining for beta-catenin IHC. An association was found between reduced expression of E-cadherin and beta-catenin. Moreover, an association was detected between reduced expression of E-cadherin and diffuse histotype.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
Our results support the hypothesis that alterations of E-cadherin and beta-catenin play a role in the initiation and progression of gastric cancer.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 265 266 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 858 865 847 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 973 974 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 975 976 964 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1250 1251 1239 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1252 1253 1241 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 739 744 <span type="species:ncbi:9606">human</span>
E-cadherin (120 kDa; chromosome 16q) is a classical cadherin and forms the key functional component of adherence junctions between epithelial cells [1]. It is bound via a series of undercoat proteins, the catenins (alpha, beta and gamma) to the actin cytoskeleton [1]. This linkage between transmembranous cadherins and actin filaments of the cytoskeleton is necessary to form strong cell-cell adhesion. An intact E-cadherin - catenin complex is required for maintenance of normal intercellular adhesion. In light of this, several groups have proposed that in carcinomas, E-cadherin functions as an invasion suppressor molecule such that its loss permits or enhances the invasion of adjacent normal tissues. Immunohistochemical studies in human cancers, including gastric cancer, have frequently shown that a proportion of invasive carcinomas and carcinomas in situ show aberrant levels of E-cadherin and/or catenin expression in comparison to their related normal tissue [2-4]. In general, E-cadherin and catenin staining is strong in well-differentiated cancers that maintain their cell adhesiveness and are less invasive, but is reduced in poorly-differentiated tumours which have lost their cell-cell adhesion and show strong invasive behaviour [2,3].
###end p 10
###begin p 11
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
E-cadherin is involved in contact inhibition of cell growth by inducing cell cycle arrest [5]. It has the ability to inhibit cell proliferation by the upregulation of p27 involved in the cell cycle regulation [5], although the mechanism by which E-cadherin regulates p27 is still unclear. Therefore, E-cadherin, generally described as an invasion suppressor [6], can act as a major growth/proliferation suppressor.
###end p 11
###begin p 12
###xml 79 80 76 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 450 451 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1282 1283 1255 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
An important function of beta-catenin in cell signalling, has been elucidated [7]. In the absence of a mitotic signal from outside the cell, beta-catenin is sequestered in a complex with the adenomatous polyposis coli (APC) gene product, a serine threonine glycogen synthetase kinase (GSK-3beta) and an adapter protein axin (or a homologue conductin), enabling phosphorylation and degradation of free beta-catenin by the ubiquitin-proteasome system [8]. When a mitotic signal is delivered by the Wnt pathway, by association of the Wg/Wnt family of secreted glycoproteins and their membrane receptor frizzled, it leads to activation of the dishevelled (Dsh) protein, which is recruited to the cell membrane. The activated Dsh downregulates the protein complex, so that it can no longer phosphorylate beta-catenin, which is then not degraded. The release of beta-catenin from the phosphorylation and degradation complex promotes beta-catenin stabilization and signalling. This results in an increase of free cystolic beta-catenin which translocates to the nucleus and directly binds the transcription factors Lef and Tcf, leading to the activation of gene expression. Therefore beta-catenin performs distinct functions in E-cadherin-mediated cell-cell adhesion and in Wnt signalling [8].
###end p 12
###begin p 13
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 793 795 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 796 798 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1150 1152 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1153 1155 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1358 1360 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 249 254 <span type="species:ncbi:9606">human</span>
Loss of the E-cadherin locus on the long arm of chromosome 16 (16q22) occurs in gastric (24%), hepatocellular (50%), lobular breast (50-100%) and oesophageal (66%) carcinomas [4,9-12]. There have been several reports on E-cadherin gene mutations in human cancers [13]. In poorly-differentiated tumours, such as lobular breast cancer and diffuse-type gastric cancer, E-cadherin mutations play an important role in tumour development [14,15]. Several studies have reported germline mutations in the E-cadherin gene in families with an inherited diffuse type of gastric cancer [16,17]. Only a minority of gastric cancers can be accounted for by E-cadherin mutations. Frequent somatic mutations of beta-catenin gene have been found in small colorectal adenomas and intestinal type gastric cancer [18,19]. Most of the mutations involved the loss of serines or threonines from the GSK-3beta phosphorylation region. Genetic alterations in beta-catenin abolishing cell-cell adhesiveness have been observed in two gastric cancer cell lines, HSC39 and 40A; both derive from the same signet ring cell carcinoma of the stomach and show a diffuse growth pattern [20,21]. This mutation results in a truncated beta-catenin that lacks the region for interaction with beta-catenin. Transfection of these cell lines with wild-type beta-catenin restores cellular adhesiveness [21].
###end p 13
###begin p 14
Here, we performed E-cadherin and beta-catenin gene mutation and expression analysis in a series of 50 primary gastric tumours in order to understand better the involvement of the alterations of E-cadherin and beta-catenin in the carcinogenesis of gastric cancer.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Samples
###end title 16
###begin p 17
###xml 157 158 157 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 1026 1033 <span type="species:ncbi:9606">patient</span>
Included in the study were 50 tumours and corresponding normal samples, of which two tumours (17 and 23) were from the same family, the rest sporadic (Table 1). These cases were diagnosed by the Department of Pathology, University Hospital of Iceland. Tissue was obtained freshly on the day of surgery or from paraffin-embedded material. Information concerning the tumour stage, histotype and grade was also acquired from the same department. DNA for PCR was isolated by the proteinase K treatment [22]. RNA for RT-PCR was extracted using Tri Reagent (Molecular Research Center, INC. USA). For the A592T mutation, we screened 187 normal individuals, 280 breast and 444 other cancer patients with colon and rectum, lung, endometrium, ovary, testis, kidney, thyroid carcinomas and sarcomas. All individual identifiers were removed from the control samples prior to analysis, and investigators were thus blinded to the identification of samples which can no longer be traced to specific individuals. Consent was presumed for the patient samples. For cases 294 and 728 with A592T mutation, we analyzed their pedigrees and found that there were no other cancer cases in the pedigree of case 294, but there were other 5 cancer cases in the pedigree of case 728, including 2 prostate cancers, 1 skin cancer, 1 lung cancer and 1 cancer of unclear origin.
###end p 17
###begin p 18
Summary of alterations of E-cadherin and beta-catenin in a series of 50 gastric tumours.
###end p 18
###begin p 19
###xml 394 397 <span type="species:ncbi:9685">cat</span>
###xml 530 533 <span type="species:ncbi:9685">cat</span>
###xml 617 620 <span type="species:ncbi:9685">cat</span>
T, tumour (size and invasiveness); N, node (degree of metastasis); M, metastasis; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, not differentiated; diff, diffuse (degree of differentiation=G4); mi, mixed; int, intestine; met, metastatic tumour probably from stomach tumour; squ, squamous epithelial; LOH, loss of heterozygosity; E-cad, E-cadherin; beta-cat, beta-catenin; IHC, immunohistochemistry; cd, codon; UTR, untranslated region; +, positive LOH, aberrant E-cad mRNA, E-cad and beta-cat IHC;-, negative LOH, E-cadherin gene mutation, aberrant E-cad mRNA, E-cad and beta-cat IHC; ND, not determined or not done; +/-, ++/- and +++/-, more than 50% cells positive; -/+, -/++ and -/+++, more than 50% cells negative; *, somatic mutation; diamond, germline mutation; club suit symbol, insertion of intron 7 between exons 7 and 8, stop codon 374; â™¥, deletion of last 72 bases of exon 7, exon 8 and first 124 bases of exon 9, stop codon 322; spades, deletion of exons 8 and 9; deletion of last 84 bases of exon 8, stop codon 358; nabla, these samples also showed cytoplasmic staining for beta-catenin IHC.
###end p 19
###begin title 20
LOH determination
###end title 20
###begin p 21
###xml 515 517 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Microsatellite markers used for LOH analysis of chromosome 16q were: D16S503, D16S496, D16S421, D16S545 and D16S512 for the region 16q22.1 containing E-cadherin locus (Genome Database). The polymerase chain reaction (PCR) products were separated in an acrylamide sequencing gel and transferred to a positively-charged nylon membrane, Hybond-N+ (Amersham, Aylesbury, UK) and baked for at least 2 h at 80degreesC. The non-radioactive detection method used to visualize the PCR products has been described previously [23]. Autoradiograms were inspected visually by at least two reviewers, comparing the intensity of alleles from normal and tumour DNA. The absence or a significant decrease of one allele in the tumour compared to the normal reference sample was considered as LOH.
###end p 21
###begin title 22
Mutation screening
###end title 22
###begin p 23
###xml 308 309 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
All 16 exons of E-cadherin gene and exon 3 of beta-catenin gene were screened for inactivation mutations with a PCR-SSCP (single strand conformation polymorphism) analysis on genomic DNA templates. The primers for E-cadherin and beta-catenin used in the SSCP analysis were described in our previous article [4] and Park et al. [1999], respectively, and ordered from Pharmacia Biotech or TAG Copenhagen A/S. Genomic DNA was used at 30 ng per 25 mul reaction mixture containing 5 pmol of the forward and reverse primers, 2.5 nmol of each dNTP, 0.5 units of DynaZyme polymerase. The samples were amplified in 35 cycles composed of 30 s of denaturation at 94degreesC, 30 s of annealing at 55-70degreesC, and finally 60 s of extension at 72degreesC. A hot start was used by adding the enzyme in first cycle at around 70degreesC, after a preincubation time of 5 min at 94degreesC. A 4 mul aliquot of PCR products was mixed with 7 mul of formamide dye (95% formamide, 0.05% bromophenol blue and 0.05% xylene cyanol), denatured at 94degreesC for 10 min and snapcooled on ice. Aliquots of 2 mul were analysed simultaneously on two non-denaturing polyacrylamide gels (5% acrylamide with 2% cross linking), either containing 5% glycerol or lacking glycerol. Electrophoresis was performed in 1x TBE on vertical gels at 6w overnight or for 6 h at room temperature. The PCR products were visualized as the microsatellite markers. Samples with abnormal mobility bands were amplified again for 35 cycles as described above. A 5 mul aliquot of PCR products was then incubated with 10 U exonulease I and 2 U shrimp alkaline phosphatase to remove excessive primers and dNTPs (US70995, Amersham). Sequences of both strands were determined by thermo sequenase DNA polymerase (Thermo Sequenase Radiolabeled Terminator Cycle Sequencing Kit, Amersham) using the two original PCR primers. We performed the A592T mutation analysis on those cancers, except the cancer of unclear origin, in the family of case 728 using direct sequencing.
###end p 23
###begin title 24
Aberrant mRNA screening
###end title 24
###begin p 25
###xml 340 342 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
1-5 mug of the total RNA was reversely transcribed into cDNA using first strand cDNA synthesis kit (Amersham Pharmacia Biotech). All samples were examined for E-cadherin cDNA deletions and insertions. E-cadherin cDNA was amplified using primer pairs Ex7-rEx10/2 and Ex9/2a-rEx11 for the region of exons 7-10 encoding calcium binding sites [24]. PCR products were visualized by agarose gel electrophoresis. Abnormal fragments were excised and sequenced using forward and reverse primers to determine the boundaries of the deletions and insertions. Here, we used BigDye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer, Foster City, CA) and automated sequencer ABI PRISMtrade mark 3100 (Perkin-Elmer) for sequencing
###end p 25
###begin title 26
Immunohistochemical staining
###end title 26
###begin p 27
###xml 175 179 <span type="species:ncbi:9925">Goat</span>
Immunohistochemistry for E-cadherin and beta-catenin was performed on 5-mum sections from paraffin-embedded tumour tissue blocks with monoclonal antibodies E-cadherin 5H9 and Goat Anti-Catenin Beta (Research Diagnostic, Inc. NJ, USA), respectively, using the antigen retrieval protocol described by Hazelbag et al. [1995]. Tumours were graded by intensity of staining as negative (-), weakly positive (+), moderately positive (++) and strongly positive (+++).
###end p 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
###xml 5 6 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
A Chi2 test or Fisher's exact test was used to assess the relationship between the above parameters.
###end p 29
###begin title 30
Results
###end title 30
###begin p 31
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
The frequency of LOH at 16q22.1 region was 75% (Table 1).
###end p 31
###begin p 32
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Three tumours (6%) showed the same missense mutation A592T of exon 12, of which 2 cases had germline mutation, and one case had somatic mutation. Information for detected polymorphisms was included in Table 1. Three of 187 (1.6%) normal individuals and 1 of 280 (0.36%) breast tumours showed this germline mutation. The mutation was not found in 444 other tumours (Table 2).
###end p 32
###begin p 33
Frequency of A592T missense mutation in gastric cancer, other cancer and normal individuals
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
* including colon and rectum, lung, endometrium, ovary, testis, kidney, thyroid carcinomas and sarcomas.
###end p 34
###begin p 35
Additionally, 3 of 280 breast tumours showed another missense mutation GCC(Ala)-->TCC(Ser) at the identical codon 592, of which 2 cases were germline mutation; the third was unclear because the normal tissue was unavailable. The histological type of the 4 breast tumours was ductal.
###end p 35
###begin p 36
###xml 45 52 <span type="species:ncbi:9606">patient</span>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
In the family of case 728, we found that the patient with skin cancer and one of the patients with prostate cancer showed the same germline mutation as case 728. Interestingly, no mutations were detected in the tumour samples of these two cases. Probably, the mutated alleles were lost during tumour development. The onset ages for the cases with germline mutations in the pedigree were 78 years for case 728, 73 years for the skin cancer and 76 years for the prostate cancer.
###end p 36
###begin p 37
We did not detect mutation by SSCP and DNA sequencing in exon 3 of the beta-catenin gene in the 50 gastric tumours.
###end p 37
###begin p 38
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Seven gastric tumours showed aberrant transcripts of the E-cadherin. Tumours 360, 369, 568, 717 and 750 displayed insertion of intron 7 between exons 7 and 8. Tumour 755 showed deletion of last 72 bases of exon 7, exon 8 and first 124 bases of exon 9. Tumour 808 displayed two aberrant mRNAs, of which one had deletion of exons 8 and 9, and one case with deletion of last 84 bases of exon 8 (Table 1).
###end p 38
###begin p 39
###xml 552 553 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 677 678 663 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Finally, we performed immunohistochemical staining of E-cadherin and beta-catenin. A regional variation of the staining was detected across the tumours. The scorings +/-, ++/- and +++/- refer to more than 50% cells positive, and scorings -/+, -/++ and -/+++ indicating more than 50% cells negative. Negative (-) or reduced (-/+, -/++, -/+++ and +/-) expression of E-cadherin and beta-catenin was detected in 21/50 (42%) and 14/50 (28%) cases, respectively. Furthermore, for beta-catenin IHC, 11 tumours also showed positive cytoplasmic staining (Table 1). A significant association was found between negative or reduced expression of E-cadherin and beta-catenin (p = 0.048, Chi2 test). Also we found an association between reduced expression of E-cadherin and diffuse histotype (p = 0.04, Fisher's exact test).
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 469 470 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1131 1133 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1822 1824 1822 1824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1896 1897 1896 1897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1898 1900 1898 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 2100 2102 2100 2102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 2343 2345 2343 2345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 820 825 <span type="species:ncbi:9606">human</span>
The high frequency of LOH at 16q22.1 region strongly suggests that there are one or more tumour suppressor genes in this region, whose loss could trigger carcinogenesis of gastric cancer. The E-cadherin gene has been mapped to chromosome 16q22.1 [26]. The reduced expression and gene mutations of E-cadherin in several types of cancers including gastric and lobular breast cancer have been identified, indicating that the E-cadherin gene is a tumour suppressor gene [2-4], [13-17,27]. In this study 3 cases (6%) showed the identical missense mutation A592T. The calcium-binding motifs located in the extracellular domains 1-5 are regarded as the key element for the function of E-cadherin, since a synthetic molecule with a single amino-acid substitution in a calcium-binding motif showed no adhesiveness [28]. Also, in human cell line MKN45 from gastric cancer, which lacked tight cell-cell adhesion, a 4-amino-acid deletion was found at the boundary between exons 6 and 7, which was considered to alter the conformation surrounding the key calcium-binding motifs and to abolish the adhesive property of the E-cadherin molecules [29]. The single amino-acid substitution in the present study is located within the fifth extracellular domain of E-cadherin, where a calcium-binding motif could exist. It is conceivable, therefore, that the mutations in the three cases also destroyed function of the E-cadherin. Interestingly, the three cases also showed LOH at 16q22.1 containing the E-cadherin locus. So it can be considered that two genetic events resulting in inactivation of the gene occurred in the two alleles of E-cadherin gene, respectively. The findings above indicated that the E-cadherin gene is a tumour-suppressor gene because it is in accordance with the classical two-hit theory for tumour suppressor genes [30]. Previous studies in lobular breast cancer also support this opinion [4,14]. In cell line MKN45 mentioned above (poorly differentiated adenocarcinoma) with weak cell-cell adhesion, a 12-bp in frame deletion of E-cadherin gene and loss of the wild type allele were detected [29]. But this cell line still showed strong expression of mRNAs and proteins, suggesting that not only reduced expression but also structural abnormalities themselves may result in inactivation of the E-cadherin-mediated cell adhesion system [29]. Therefore, a single amino-acid substitution found in this study may cause structural changes of E-cadherin and result in limited cell-cell adhesion, although two of the cases (23 and 294) showed sufficient protein expression.
###end p 41
###begin p 42
###xml 980 982 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1249 1251 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Interestingly, the same sequence variant of somatic and germline mutation was found simultaneously in different gastric patients. Case 23 with somatic mutation had an onset age of 56 years, but cases 294 and 728 with germline mutation had onset ages of 71 and 78 years, respectively. One explanation for this phenomenon could be that loss of second allele of E-cadherin in case 23 occurred very early, thereby triggerring carcinogenesis relatively early in case 23. But there is another possibility that this mutation in case 23 played a role only in progression of the tumour, but not in the initiation, where other genetic events could probably be responsible for the initiation of the gastric cancer. But cases 294 and 728 with germline mutations had late onset age. This may be because the inactivation of another allele occurred very late. An article reported that the obligatory carriers with truncated mutations in E-cadherin gene in their 80s and 90s remained unaffected [31]. Therefore, further identification of genetic and/or environmental modifiers that might account for the variable age of onset should be carried out. Specially, case 294 had three tumours in the stomach, which is in line with genetic tumours usually being multiple [30].
###end p 42
###begin p 43
The frequency (6%) of mutation A592T in 50 gastric tumours is almost four-fold that in normal population, suggesting again that this mutation indeed contributed to the tumourigenesis in a subset of gastric tumours. Futhermore, 0.36% of breast tumours, and no other tumours, showed identical germline mutation, indicating that there could be a histological difference for this mutation in gastric cancer and other cancer.
###end p 43
###begin p 44
Only other two cases exhibited A592T mutation in the family of case 728. Specially, this mutation was detected only in corresponding normal tissue, but not in the tumour tissue, suggesting that the mutated alleles were lost during the tumourigenesis. From these we can conclude that this mutation may not play a role in the tumourigenesis of prostate and skin cancer, but it could be gastric-cancer specific.
###end p 44
###begin p 45
We conclude that the A592T mutation may increase the lifetime risk of developing gastric cancer, but is clearly a sequence variant of low penetrance. Our findings of two different sequence variants at codon 592 (A592T and A592S), as germline and somatic mutations, suggest that this codon is a hotspot of mutations in tumour pathogenesis.
###end p 45
###begin p 46
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 297 302 <span type="species:ncbi:10090">mouse</span>
The breakpoints for insertions of intron 7 and deletion of exons 8 and 9 are at splicing sites, in accordance with "GU-AG" rule for mRNA splicing. It may be speculated that these alterations were not generated by alternative splicing, since no evidences for alternative splicing were found within mouse E-cadherin gene [32] and no aberrant mRNAs were detected in noncancerous tissues. The mutations at splicing sites ought to be responsible for the alterations of E-cadherin mRNAs, although no mutations were found on DNA level in this study, presumably because the SSCP used for mutation screening has a low efficiency. An additional 2 deletions showed breakpoints at non-splicing sites, whose splicing is not in line with "GU-AG" rule, possibly indicating that a rearrangement in genomic level may cause the aberrant mRNAs. Previous studies have shown skipping of exon 8 or 9 in gastric cancer [24,33]. These aberrations may result in E-cadherins losing calcium-binding motifs due to lack of exons 8 and 9, and truncated molecules because of frameshift mutations caused by insertions and deletions, finally facilitating scattering of carcinoma cells.
###end p 46
###begin p 47
###xml 107 108 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 393 395 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 632 634 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1099 1100 1090 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1655 1656 1637 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 2217 2218 2196 2197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 2408 2409 2387 2388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1085 1090 <span type="species:ncbi:9606">human</span>
###xml 2207 2215 <span type="species:ncbi:9606">patients</span>
Reduced expression of E-cadherin and beta-catenin has been found in some cancers including gastric cancer [8]. Heterogeneous or unstable expression for both E-cadherin and beta-catenin across the tumours was found. It has been demonstrated that in 40% of adenocarcinomas E-cadherin levels were raised in their intravascular tumour components in comparison to their extravascular compartments [34]. One explanation may be that entrance of a carcinoma into an intravascular compartment is associated with an upregulation of E-cadherin expression, and that subsequent exit into extravascular tissues is associated with downregulation [35]. Since E-cadherin and beta-catenin are the crucial components to form cell-cell adhesion complex, loss of them may result in the disruption of the function of the complex, which may cause weak cell-cell adhesion and confer invasive properties on a tumour. Furthermore, reduced cell-cell adhesion is associated with loss of contact inhibition of proliferation, thereby allowing escape from growth control signal, finally triggering carcinogenesis of human cancer [8]. In this study, an association between abnormal expression of E-cadherin and beta-catenin was found, suggesting that loss of E-cadherin binding may cause a redistribution of beta-catenin from the cell membrane to the cytoplasm. The increased free beta-catenin in the cytoplasm could translocate to the nucleus and lead to activation of gene expression. This is supported by the findings that two cases (676 and 738) showed negative staining in the inner surface of membrane and positive staining in cytoplasm, simultaneously. But other 9 tumours (table 1) showing moderate or strong staining in membrane also exhibited positive staining in cytoplasm, suggesting that the normal degradation of the free beta-catenin in cytoplasm is inhibited. Also, we found an association between abnormal expression of E-cadherin and diffuse histotype, indicating that the alterations of the E-cadherin may play a role in poorly-differentiated gastric tumours. Interestingly, aberrant expression of E-cadherin and/or the catenins has been shown to be an independent prognostic marker for short survival in gastric cancer patients [8]. Of particular interest is the finding that E-cadherin is an independent predictor of occult lymph node and micrometastasis in nodes classified as No by routine histopathological methods [8].
###end p 47
###begin title 48
Conclusions
###end title 48
###begin p 49
Our results support that alterations of E-cadherin and beta-catenin play a role in the initiation and progression of gastric cancer. Expression of both genes are reduced in gastric cancer, but the mechanism of downregulation is not clear. LOH, mutations and alterations in RNA splicing could explain a part of the downregulation of the E-cadherin in gastric cancer.
###end p 49
###begin title 50
Competing interests
###end title 50
###begin p 51
None declared
###end p 51
###begin title 52
Pre-publication history
###end title 52
###begin p 53
The pre-publication history for this paper can be accessed here:
###end p 53
###begin p 54

###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
This work was supported by the Icelandic Research Council, the University of Iceland Science Fund and the Icelandic Cancer Society.
###end p 56
###begin article-title 57
E-cadherin mediated adhesion system in cancer cells.
###end article-title 57
###begin article-title 58
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
###end article-title 58
###begin article-title 59
###xml 62 67 <span type="species:ncbi:9606">human</span>
Expression of e-cadherin, alpha-catenins and beta-catenins in human gastric carcinomas - correlation with histology and tumor progression.
###end article-title 59
###begin article-title 60
###xml 56 61 <span type="species:ncbi:9606">human</span>
Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer.
###end article-title 60
###begin article-title 61
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27 (KIP1).
###end article-title 61
###begin article-title 62
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.
###end article-title 62
###begin article-title 63
Cadherin and catenin biology represent a global mechanism for epithelial cancer progression.
###end article-title 63
###begin article-title 64
###xml 50 55 <span type="species:ncbi:9606">human</span>
E-cadherin-catenin cell-cell adhesion complex and human cancer.
###end article-title 64
###begin article-title 65
Adherens junction proteins in tumour progression.
###end article-title 65
###begin article-title 66
###xml 60 65 <span type="species:ncbi:9606">human</span>
Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma.
###end article-title 66
###begin article-title 67
E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus.
###end article-title 67
###begin article-title 68
Analysis of microsatellite regions and DNA ploidy pattern in signet ring cell carcinomas of the stomach.
###end article-title 68
###begin article-title 69
###xml 17 22 <span type="species:ncbi:9606">human</span>
Mutations of the human E-cadherin (CDH1) gene.
###end article-title 69
###begin article-title 70
###xml 52 57 <span type="species:ncbi:9606">human</span>
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain.
###end article-title 70
###begin article-title 71
E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas.
###end article-title 71
###begin article-title 72
E-cadherin germline mutations in familial gastric cancer.
###end article-title 72
###begin article-title 73
Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer.
###end article-title 73
###begin article-title 74
beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas.
###end article-title 74
###begin article-title 75
Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer.
###end article-title 75
###begin article-title 76
###xml 137 142 <span type="species:ncbi:9606">human</span>
A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines.
###end article-title 76
###begin article-title 77
###xml 96 101 <span type="species:ncbi:9606">human</span>
Loss of E-cadherin-dependent cell - cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39.
###end article-title 77
###begin article-title 78
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome.
###end article-title 78
###begin article-title 79
E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.
###end article-title 79
###begin article-title 80
Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded tissue: a comparison of various antigen retrieval systems using microwave heating and proteolytic pretreatments.
###end article-title 80
###begin article-title 81
###xml 71 76 <span type="species:ncbi:9606">human</span>
Characterization and chromosomal localization of the gene encoding the human cell adhesion molecule uvomorulin.
###end article-title 81
###begin article-title 82
Expression of E- and P-cadherin in gastric carcinomas.
###end article-title 82
###begin article-title 83
Single amino acid substitution in one calcium binding site of uvomorulin abolish the adhesive function.
###end article-title 83
###begin article-title 84
###xml 29 34 <span type="species:ncbi:9606">human</span>
E-cadherin gene mutations in human gastric carcinoma cell lines.
###end article-title 84
###begin article-title 85
Hereditary cancer, oncogenes, and antioncogenes.
###end article-title 85
###begin article-title 86
Identification of germ-line E-cadherin mutations in gastric cancer families of European origin.
###end article-title 86
###begin article-title 87
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
The structure of the gene coding for the mouse cell adhesion molecule uvomorulin.
###end article-title 87
###begin article-title 88
###xml 62 67 <span type="species:ncbi:9606">human</span>
Exon skipping in the E-cadherin gene transcript in metastatic human gastric carcinomas.
###end article-title 88
###begin article-title 89
Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas.
###end article-title 89
###begin article-title 90
The molecular histology of neoplasia: the role of the cadherin/catenin complex.
###end article-title 90

